Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
Authors:ID Mencinger, Marina (Author)
ID Mangaroski, Dushan (Author)
ID Bokal, Urška (Author)
Files:URL URL - Source URL, visit https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647786/pdf/raon-55-491.pdf
 
.pdf PDF - Presentation file, download (718,26 KB)
MD5: 1FC8E59EA70A94614F56BEB76B262E3E
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Background. Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.Patients and methods. 62 patients with mUC, treated at the Institute of Oncology Ljubljana between May 8th 2018 and Dec 31st 2019, were included. Response rates and immune-related adverse events (irAE) were collected. Progression-free survival and overall survival times were assessed using the Kaplan-Meier method. The Cox propor-tional hazards model was applied to identify the factors affecting survival. Results. Of 62 patients, five (8.1%) have not yet been evaluated and 20 (32%) died prior to the first radiographic evaluation. We observed clinical benefit in 19 (33%), objective response in 12 (21%), and complete response in five (9%) patients. Median overall survival for the whole population was 6.8 (95% CI, 2.6–11.0), for platinum-naïve 8.7 (95% CI: 0.8–16.5), and for the platinum-treated group 6.8 (95% CI, 3.7–10) months. At the 5.8 (0.3–23.1) month median follow-up, the median duration of the response was not reached. IrAE occurred in 20 (32%) patients and seven (11%) of them discontinued the treatment. Multivariate analysis in platinum-treated patients showed that a treatment-free interval of more than six months was prognostic for overall survival (OS). Conclusions. Responses to atezolizumab led to long disease remission in a subset of our patients. The median OS in our real-world population was compromised by a large percentage of patients with poor ECOG performance status (PS). A treatment-free interval from chemotherapy was associated with the longer survival of platinum-treated pa-tients with mUC receiving further atezolizumab.
Keywords:PD-L1 inhibitor, urothelial cancer, bladder, atezolizumab
Publication status:Published
Publication version:Version of Record
Publication date:01.01.2021
Publisher:Association of Radiology and Oncology
Year of publishing:2021
Number of pages:str. 491-498, XII
Numbering:Vol. 55, no. 4
Source:Ljubljana
PID:20.500.12556/DiRROS-19673 New window
UDC:616-006
ISSN on article:1318-2099
DOI:10.2478/raon-2021-0021 New window
COBISS.SI-ID:92836867 New window
Copyright:by Authors
Publication date in DiRROS:23.07.2024
Views:506
Downloads:264
Metadata:XML DC-XML DC-RDF
:
MENCINGER, Marina, MANGAROSKI, Dushan and BOKAL, Urška, 2021, Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice. Radiology and oncology [online]. 2021. Vol. 55, no. 4, p. 491–498, xii. [Accessed 20 April 2025]. DOI 10.2478/raon-2021-0021. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=19673
Copy citation
  
Share:Bookmark and Share


Searching for similar works...Please wait....
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Keywords:zaviralec PD-L1, rak sečnih organov, mehur, kemoterapija


Back